Ensysce Biosciences Inc ENSC
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-12-01 |
| Shares Out. | 14,690,000 |
| Website | ensysce.com/ ↗ |
| Phone | 18582634196 |
| Employees | 10 |
| Revenue | $960,999 |
| Gross Profit | $960,999 |
| Net Income | -$3.6M |
| Free Cash Flow | -$9.7M |
| Total Assets | $2.2M |
| Total Liabilities | $2.8M |
| Equity | -$669,012 |
About Ensysce Biosciences Inc
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Ensysce Biosciences Inc is a publicly traded company under the ticker symbol ENSC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2024-07-01)